Literature DB >> 22054881

Molecular biology of lung cancer: clinical implications.

Jill E Larsen1, John D Minna.   

Abstract

Lung cancer is a heterogeneous disease clinically, biologically, histologically, and molecularly. Understanding the molecular causes of this heterogeneity, which might reflect changes occurring in different classes of epithelial cells or different molecular changes occurring in the same target lung epithelial cells, is the focus of current research. Identifying the genes and pathways involved, determining how they relate to the biological behavior of lung cancer, and their utility as diagnostic and therapeutic targets are important basic and translational research issues. This article reviews current information on the key molecular steps in lung cancer pathogenesis, their timing, and clinical implications. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22054881      PMCID: PMC3367865          DOI: 10.1016/j.ccm.2011.08.003

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  489 in total

1.  PIK3CA mutation status in Japanese lung cancer patients.

Authors:  Osamu Kawano; Hidefumi Sasaki; Katsuhiko Endo; Eriko Suzuki; Hiroshi Haneda; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2006-08-22       Impact factor: 5.705

2.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

Review 3.  Telomerase activity in human cancer.

Authors:  J W Shay; W E Wright
Journal:  Curr Opin Oncol       Date:  1996-01       Impact factor: 3.645

4.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

5.  MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Authors:  B E Johnson; E Russell; A M Simmons; R Phelps; S M Steinberg; D C Ihde; A F Gazdar
Journal:  J Cell Biochem Suppl       Date:  1996

6.  DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.

Authors:  Qinghua Feng; Stephen E Hawes; Joshua E Stern; Linda Wiens; Hiep Lu; Zhao Ming Dong; C Diana Jordan; Nancy B Kiviat; Hubert Vesselle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

7.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Authors:  Elena Gallardo; Alfons Navarro; Nuria Viñolas; Ramon M Marrades; Tania Diaz; Bernat Gel; Angels Quera; Eva Bandres; Jesus Garcia-Foncillas; Jose Ramirez; Mariano Monzo
Journal:  Carcinogenesis       Date:  2009-09-07       Impact factor: 4.944

8.  Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.

Authors:  Kip A West; Ilona R Linnoila; Steven A Belinsky; Curtis C Harris; Phillip A Dennis
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer.

Authors:  K M Fong; Y Kida; P V Zimmerman; M Ikenaga; P J Smith
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

10.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

View more
  80 in total

1.  Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene.

Authors:  Elena V Antontseva; Marina Yu Matveeva; Natalia P Bondar; Elena V Kashina; Elena Yu Leberfarb; Leonid O Bryzgalov; Polina A Gervas; Anastasia A Ponomareva; Nadezhda V Cherdyntseva; Yury L Orlov; Tatiana I Merkulova
Journal:  J Biosci       Date:  2015-12       Impact factor: 1.826

2.  Analysis of Chromosome 3, 7 and 8 Centromeric Regions in Bronchial Lavage Specimens by FISH.

Authors:  Sezen Atasoy; Salih Serdar Erturan; Nail Yılmaz; Dilhan Kuru; Ayşe Çırakoğlu; Şükriye Yılmaz; Ayhan Deviren
Journal:  Turk Thorac J       Date:  2016-10-01

3.  VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.

Authors:  Wenjing Zhang; Yijun Gao; Peixue Li; Zhubing Shi; Tong Guo; Fei Li; Xiangkun Han; Yan Feng; Chao Zheng; Zuoyun Wang; Fuming Li; Haiquan Chen; Zhaocai Zhou; Lei Zhang; Hongbin Ji
Journal:  Cell Res       Date:  2014-01-24       Impact factor: 25.617

Review 4.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

Review 5.  The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club.

Authors:  Isabelle Opitz; Thomas A D'Amico; Gaetano Rocco
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

6.  Expression profile of Oct-4 lung cancer-specific marker prior and subsequent to a salirasib treatment regime.

Authors:  Xiang Ao; Jie Zhou; Hong Ling Liang; Ming Jiang; Hong Sheng Li
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

7.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

8.  Telomere Length and Lung Cancer Mortality among Heavy Smokers.

Authors:  Jennifer A Doherty; Laurie Grieshober; John R Houck; Matthew J Barnett; Jean De Dieu Tapsoba; Mark Thornquist; Ching-Yun Wang; Gary E Goodman; Chu Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-09       Impact factor: 4.254

9.  Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.

Authors:  Mitsuo Sato; Jill E Larsen; Woochang Lee; Han Sun; David S Shames; Maithili P Dalvi; Ruben D Ramirez; Hao Tang; John Michael DiMaio; Boning Gao; Yang Xie; Ignacio I Wistuba; Adi F Gazdar; Jerry W Shay; John D Minna
Journal:  Mol Cancer Res       Date:  2013-02-28       Impact factor: 5.852

10.  Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Authors:  N Sunaga; K Kaira; H Imai; K Shimizu; T Nakano; D S Shames; L Girard; J Soh; M Sato; Y Iwasaki; T Ishizuka; A F Gazdar; J D Minna; M Mori
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.